Idrees Mian
Overview
Explore the profile of Idrees Mian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
644
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nair N, Jiang Q, Wei J, Misra V, Morrow B, Kesserwan C, et al.
Cell Rep Med
. 2023 Feb;
4(2):100938.
PMID: 36773602
Malignant mesothelioma is an aggressive cancer with limited treatment options and poor prognosis. A better understanding of mesothelioma genomics and transcriptomics could advance therapies. Here, we present a mesothelioma cohort...
2.
Ghafoor A, Mian I, Wagner C, Mallory Y, Agra M, Morrow B, et al.
JTO Clin Res Rep
. 2021 Oct;
2(10):100231.
PMID: 34661178
Introduction: PARP inhibition may enhance antitumor responses in -associated mesothelioma by inducing synthetic lethality. Methods: A single-center, nonrandomized, phase 2 trial was conducted, in which patients with refractory mesothelioma were...
3.
Hassan R, Alewine C, Mian I, Spreafico A, Siu L, Gomez-Roca C, et al.
Cancer
. 2020 Sep;
126(22):4936-4947.
PMID: 32870522
Background: LMB-100 is an antibody-toxin conjugate with an antimesothelin Fab linked to a 24-kilodalton portion of Pseudomonas exotoxin A with mutations that decrease immunogenicity. The objective of the current first-in-human...
4.
Jiang Q, Ghafoor A, Mian I, Rathkey D, Thomas A, Alewine C, et al.
Sci Transl Med
. 2020 Jul;
12(550).
PMID: 32611684
LMB-100 is an immunotoxin targeting the cell surface protein mesothelin, which is highly expressed in many cancers including mesothelioma. Having observed that patients receiving pembrolizumab off protocol after LMB-100 treatment...
5.
Thomas A, Mian I, Tlemsani C, Pongor L, Takahashi N, Maignan K, et al.
Chest
. 2020 May;
158(4):1723-1733.
PMID: 32464188
Background: Small cell lung cancer (SCLC) has the strongest association with smoking among lung cancers. The characteristics of never smokers with SCLC is not known. Research Question: Are the clinical...
6.
Mian I, Padiernos E, Hassan R, Ghafoor A
Lancet Oncol
. 2020 Feb;
21(2):e117.
PMID: 32007197
No abstract available.
7.
Mian I, Abdullaev Z, Morrow B, Kaplan R, Gao S, Miettinen M, et al.
J Thorac Oncol
. 2019 Nov;
15(3):457-461.
PMID: 31783178
Introduction: Children and young adults diagnosed with malignant mesothelioma may have unique genetic characteristics. In this study, we evaluated for the presence of the anaplastic lymphoma kinase (ALK) translocations in...
8.
Hassan R, Morrow B, Thomas A, Walsh T, Lee M, Gulsuner S, et al.
Proc Natl Acad Sci U S A
. 2019 Apr;
116(18):9008-9013.
PMID: 30975761
Survival from malignant mesothelioma, particularly pleural mesothelioma, is very poor. For patients with breast, ovarian, or prostate cancers, overall survival is associated with increased sensitivity to platinum chemotherapy due to...
9.
Ghouri Y, Mian I, Rowe J
J Carcinog
. 2017 Jul;
16:1.
PMID: 28694740
Since the 1970s, the epidemic of hepatocellular carcinoma (HCC) has spread beyond the Eastern Asian predominance and has been increasing in Northern hemisphere, especially in the United States (US) and...
10.
Mian I, Milton D, Shah N, Nieto Y, Popat U, Kebriaei P, et al.
Cancer
. 2016 Sep;
122(24):3831-3837.
PMID: 27680710
Background: Although lenalidomide maintenance therapy has demonstrated improved outcomes after autologous hematopoietic stem cell transplantation (auto-HCT) for patients with multiple myeloma (MM), the impact of the duration of this therapy...